Subsequent Event - Additional Information (Details) - USD ($) |
Mar. 31, 2026 |
Feb. 12, 2026 |
Dec. 31, 2025 |
Nov. 18, 2025 |
|---|---|---|---|---|
| Subsequent Event [Line Items] | ||||
| Nominal value | $ 0.01 | $ 0.01 | ||
| Avadel Pharmaceuticals Plc | ||||
| Subsequent Event [Line Items] | ||||
| Issued ordinary share | $ 21 | |||
| Nominal value | 0.01 | |||
| Potential additional cash payment per share upon achievement of specific milestone | 1.5 | |||
| Potential additional cash payment per share | $ 21 | |||
| Bridge Term Loan Credit Agreement | JPMorgan Chase Bank, N.A. | Avadel Pharmaceuticals Plc | ||||
| Subsequent Event [Line Items] | ||||
| Aggregate principal amount | $ 1,500,000,000 |
| X | ||||||||||
- Definition Business acquisition potential additional cash payment per share upon achievement of specific milestone. No definition available.
|
| X | ||||||||||
- Definition Per share price of saleable stock paid or offered to be paid by acquirer in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Per share or per unit amount of equity securities issued. No definition available.
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|